KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $100 million. All of the shares of the common stock to be sold in the offering will be offered by KYTHERA.
KYTHERA intends to use the net proceeds of the offering to fund the ongoing development and preparation for potential commercialization of ATX-101, including the preparation and submission of its New Drug Application, or NDA, for ATX-101, and the balance for working capital and general corporate purposes, including research and development.